Efficacy of 5-day parenteral versus intramammary benzylpenicillin for treatment of clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro.
The efficacy of parenteral (intramuscular) or intramammary (IMM) benzylpenicillin treatment for clinical mastitis caused by gram-positive bacteria susceptible to penicillin in vitro was investigated. Cows with clinical mastitis in 1 udder quarter were randomly placed into 2 treatment groups. The preliminary bacteriological diagnosis of intramammary infection (IMI) was based on on-farm culturing, and the bacteriological diagnoses were later confirmed by a quantitative PCR assay. Clinical mastitis caused by gram-positive bacteria susceptible to benzylpenicillin was treated with penicillin via either the parenteral route (20mg/kg) or IMM route (600mg) once per day for 5d. The outcome of the treatment was evaluated 3 to 4wk after the onset of the treatment. The affected quarter was examined to assess the clinical cure, and milk samples were collected from the affected quarter to determine the bacteriological cure and milk N-acetyl-β-d-glucosaminidase activity. The survival and the composite milk somatic cell counts of the treated cows were followed up for 6 and 3mo after treatment, respectively. A total of 140 cows with clinical mastitis were included in the study, 61 being treated with benzylpenicillin parenterally and 79 via the IMM route. From all quarters treated, 108 of 140 (77.1%) were cured clinically and 77 of 140 (55.0%) were cured bacteriologically. The route of treatment did not significantly affect the outcome of the treatment; 80.3% of the quarters with parenteral treatment and 74.7% of the quarters with IMM treatment showed a clinical cure, and 54.1 and 55.7% a bacteriological cure, respectively. The milk N-acetyl-β-d-glucosaminidase activity was significantly lower in the quarters with a clinical or bacteriological cure than in the quarters with no cure. The 6-mo survival and the proportion of cows with composite milk somatic cell counts <200,000/mL among the treated cows during the 3-mo follow-up period did not significantly differ between the treatment groups. In conclusion, the outcome of either parenteral or IMM benzylpenicillin treatment of clinical mastitis caused by penicillin-susceptible bacteria was similar.
Department of Therapy, Institute of Veterinary Medicine and Animal Science, Estonian University of Life Sciences, Tartu, 51014, Estonia. Electronic address: piret.kalmus@emu.ee.
P
P
Kalmus
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
H
H
Simojoki
Department of Therapy, Institute of Veterinary Medicine and Animal Science, Estonian University of Life Sciences, Tartu, 51014, Estonia.
T
T
Orro
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
S
S
Taponen
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
K
K
Mustonen
Thermo Fisher Scientific, FI-016210 Vantaa, Finland.
J
J
Holopainen
Department of Production Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Paroninkuja 20, FI-04920 Saarentaus, Finland.
S
S
Pyörälä
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002417:Cattle; D004957:Estonia; D005260:Female; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000502:physiology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D007263:Infusions, Parenteral / Q000662:veterinary; D007273:Injections, Intramuscular / Q000662:veterinary; D008414:Mastitis, Bovine / Q000188:drug therapy*; D010400:Penicillin G / Q000008:administration & dosage / Q000494:pharmacology*; D010403:Penicillin Resistance; D060888:Real-Time Polymerase Chain Reaction / Q000662:veterinary
D000900:Anti-Bacterial Agents; D010400:Penicillin G
benzylpenicillin; clinical mastitis; dairy cow; treatment route